PRIMARY STRUCTURE OF THE 'BAIT' REGION FOR PROTEINASES IN α_2 -MACROGLOBULIN

Nature of the complex

Lars SOTTRUP-JENSEN, Peter B. LØNBLAD, Terrence M. STEPANIK*, Torben E. PETERSEN, Staffan MAGNUSSON and Hans JÖRNVALL⁺

Department of Molecular Biology, University of Aarhus, 8000 Aarhus C, Denmark and [†]Department of Chemistry, Karolinska Institutet, 104 01 Stockholm, Sweden

Received 21 March 1981

1. Introduction

Most proteinase inhibitors in blood plasma, e.g., antithrombin-III, α_1 -antitrypsin, inter- α -trypsin inhibitor, are specific towards serine proteinases and form 1:1 complexes engaging the active site and thus completely inhibiting the proteinase activity. α_2 -Macroglobulin is a tetrameric glycoprotein, M_r 725 000, consisting of four apparently identical chains. 'Halfmolecules', M_r 360 000 can be obtained under nonreductive denaturing conditions [1,2]. Unlike the other inhibitors $\alpha_2 M$ can form complexes with proteinases from different classes having different substrate specificities [3-5]. Furthermore, the active site of the complexed proteinase is accessible to smaller molecules as shown by the facts that the α_2 M-trypsin can cleave synthetic substrates [6] and be inhibited by the bovine pancreatic trypsin inhibitor (Kunitz) $(M_r 6514)$ [7]. It is not accessible to larger protein substrates or inhibitors, e.g., soy bean trypsin inhibitor, M_r 20 095 [7]. However, neither zymogens such

Abbreviations: $\alpha_2 M$, α_2 -macroglobulin; TLCK, N^{α} -tosyl-Llysine chloromethyl-ketone; DIP, diisopropylphosphoryl; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TPCK, N^{α} -tosyl-L-phenylalanine chloromethyl ketone; PMSF, phenylmethanesulfonylfluoride; TFA, trifluoroacetic acid; PTH, phenylthiohydantoin; HPLC, high-performance liquid chromatography; TLC, thin-layer chromatography

* Present address: Division of Biological Sciences, National Research Council of Canada, Room 1083, 100 Sussex Drive, Ottawa, Ontario, K1A OR6, Canada

as prothrombin [8] or plasminogen [9], nor activesite-inhibited proteinases such as TLCK-trypsin [3] or DIP-thrombin [8] bind to α_2M . This indicates that the complex formation involves a proteolytic process [3]. Electron microscopy and gel electrophoresis indicate that the quaternary structure of $\alpha_2 M$ becomes more compact as a result of proteinase complex formation [5,10–12]. When incubating native α₂M with different serine proteinases (trypsin, thrombin, plasmin, plasma kallikrein or chymotrypsin) the $M_{\rm r}$ 180 000 subunits were cleaved near the middle of the polypeptide chain to produce 2 fragments of app. $M_{\rm r}$ 85 000 as seen in reducing SDS-PAGE [13]. In fact binding to $\alpha_2 M$ of proteinases from all 4 classes, namely serine, thiol, acid and metallo proteinases (EC 3.4.21-24), is accompanied by cleavage of the α_2 M subunits to M_r 85 000 fragments [4]. Recent estimates indicate [11–16] that the α_2 M-proteinase complex contains a maximum of 2 mol proteinase/ mol $\alpha_2 M$. To provide a structural basis for describing the properties of $\alpha_2 M$ its primary structure is currently being investigated. Partial sequence results from these studies [17] indicate that the subunits of $\alpha_2 M$ are identical, each being composed of ~1450 amino acid residues and having the C-terminal sequence:

-Asx-Leu-Gly-Asx-Ala The same conclusion was reached [14] regarding the identity of the subunits of $\alpha_2 M$ and the sequence of the N-terminal 13 residues was also reported [14].

At present, 1383 residues from $\alpha_2 M$ have been placed in three long, but not yet overlapped stretches and another \sim 25–50 residues are known as sequences of

smaller peptides, in all accounting for $\sim 1408-1433$ residues (L. S., T. M. S., D. M. Rider, P. B. L., T. E. P., S. M., unpublished). Therefore, it appeared reasonable to assume that the site/s cleaved in $\alpha_2 M$ during complex formation with proteinases could be identified by comparing the results of direct sequence determination of complexed and of non-complexed $\alpha_2 M$ with the already known parts of the $\alpha_2 M$ sequence.

Apart from an N-terminal segment of non-complexed $\alpha_2 M$ this report describes the sequence of a 35 residue internal stretch of $\alpha_2 M$ which contains 2 sites cleaved by elastase and 1 site cleaved by trypsin, plasmin and thrombin.

2. Materials and methods

Human $\alpha_2 M$ was prepared by Zn^{2^+} -affinity chromatography as in [16].

Human plasminogen was prepared by affinity chromatography using L-lysine Sepharose [18]. Bovine thrombin prepared earlier [19] was used after storage at -20° C. Bovine TPCK-treated trypsin was from Worthington (Freehold NJ). Porcine pancreatic elastase was a gift from Dr D. Shotton (Cambridge). Staphylococcus aureus protease [20] was from Miles (Slough). Streptokinase (further purified before use [21]) was a gift from Dr H. Niléhn (Kabi, Stockholm). Sepharose CL-4B and Sephadex G-25 were from Pharmacia (Uppsala). Benzamidine, PMSF, reagents for manual sequence analysis and standard chemicals were from Merck (Darmstadt) or from Fluka (Buchs).

Manual sequence degradation was done [22] using heptane/ethyl acetate 2:1 (v/v) [23] instead of benzene and using diethyl ether [24] to extract the anilinothiazolinones from the dried peptide film or the partly dried protein film after having cleaved with TFA. PTH derivatives were determined by HPLC [25]. Sequenator analysis of proteinase-treated $\alpha_2 M$ was performed in a Beckman 890C instrument and the resulting PTHs identified by HPLC and TLC [26]. The peptides described were isolated from enzymic digests of CNBr-fragments from α_2 M or of reduced, carboxymethylated $\alpha_2 M$ (citraconylated or not) by column chromatography and electrophoresis or chromatography on paper [17,27]. Amino acid compositions of peptides were determined after hydrolysis in 6 M HCl, 0.1% phenol at 110°C for 16–24 h using a Beckman 121MB [28]. An $E_{280\,\mathrm{nm}}^{1\%}$ = 9.1 [29] was used for $\alpha_2 M$.

3. Results

Solutions of freeze-dried $\alpha_2 M$ in 0.05 M Tris-HCl, 0.1 M NaCl (pH 8.0) clarified by centrifugation, contained 3.4–4.3 mg α_2 M/ml. Assuming that the trypsin, elastase and thrombin preparations contain 50-60% active enzyme and streptokinase-activated plasminogen [21] 80% active plasmin, an amount of proteinase was added to 15-20 ml α₂M which would give a 2-fold molar excess of active enzyme over $\alpha_2 M$. After incubating with trypsin for 1 min, plasmin for 2 min or thrombin for 60 min, 1 M benzamidine was added to a final concentration of 50-60 mM. Elastase and $\alpha_2 M$ were incubated for 1 min and then 0.1 M PMSF was added to 20 mM. Resulting $\alpha_2 M$ -proteinase complexes were precipitated by adding (NH₄)₂SO₄ to 60% saturation and centrifuging, then redissolved in 6 M urea, 0.1 M NaCl, 0.5 M HCOOH (pH 2.9) and chromatographed as shown in fig.1 for α₂M-trypsin complex.

Incubation of $\alpha_2 M$ with trypsin or elastase as described above led to the almost complete cleavage of the 4 $M_{\rm r}$ 180 000 subunits into $M_{\rm r}$ 85 000 fragments as revealed by SDS-PAGE under reducing con-




Fig.1. Gel filtration of 51 mg α_2 M that had been incubated for 60 s with 5 mg TPCK-treated trypsin. The $(NH_4)_2SO_4$ precipitate was redissolved in 6 M urea, 0.1 M NaCl, 0.5 M HCOOH (pH 2.9) and applied to a column (2.5 × 90 cm) of Sepharose CL-4B, equilibrated and eluted with the same buffer at a flow rate of 20 ml/h (5 ml fractions). The effluent was collected in 2 pools (1,2) as indicated. After desalting on a column (5 × 20 cm) of Sephadex G-25 in 0.1 M HCOOH, the solutions were freeze-dried. Both pools 1,2, together constituting the irregular main peak (A), fractions 59–82, were found to contain α_2 M half-molecules (M_r 360 000) and aggregates complexed with trypsin. The small peak (B) fractions 83–92, probably contain free trypsin. On an absorbance basis it would correspond to 15% of the added trypsin. The peak at fractions 100–110 contained residual benzamidine.

10

Ser-Val-Ser-Gly-Lys-Pro-Gln-Tyr-Met-Val-Leu-Val-Pro-Ser-Leu-Leu-His-Thr-Glu-Thr-Thr-Glu-Lys-(53 res.)-Met-




Fig.2. Amino acid sequence of residues 1-23 of human $\alpha_2 M$. Peptide nomenclature: CB-A, CB-B, CNBr-fragments; T1, tryptic peptide from reduced, carboxymethylated $\alpha_2 M$. Solid lines correspond to amino acid compositions, half arrows to manual sequence results.

ditions. However, the extent of cleavage by plasmin or thrombin was only \sim 50%.

The separation patterns obtained for $\alpha_2 M$ incubated with the other 3 proteinases were very similar to that shown in fig.1. In particular, the amount of material eluting in the corresponding peak B could account for only 10-15% of the added amount of proteinase, indicating that the complexed proteinases remained bound to $\alpha_2 M$ even under these strongly denaturing conditions.

Direct manual sequence determination through 6 steps of human $\alpha_2 M$ gave the sequence:

From this, and the structures of T1, CB-A and CB-B, the sequence of the first 23 residues of $\alpha_2 M$ was determined (fig.2). These results agree with and extend data [14] on residues 1–13 of $\alpha_2 M$. Both $\alpha_2 M$ —trypsin and $\alpha_2 M$ —elastase yielded a mixed sequence with two major residues released in each cycle of Edman degradation, one from the original N-terminus of $\alpha_2 M$ (common to both sets of data) and one from the cleavage site in $\alpha_2 M$ (tables 1,2). These two major sequences could be discriminated confidently through 12 steps using the sequenator procedure (tables 1,2).

Table 1 Major^a N-terminal sequences of proteinase-treated α , M

Position	Known sequences (fig.2,3)		Residues detected $(nmol)^b$ after proteolytic cleavage of $\alpha_2 M$ with						
	New N-terminal	Original N-terminal	Trypsin	Plasmin	Thrombin				
1	Leu	Ser	Leu(25) Ser(>10)	(Leu) (Ser)	(Leu) (Ser)				
2	Val	Val	Val(50)	(Val)	(Val)				
3	His	Ser	His(20) Ser(>10)	– (Ser)	- (Ser)				
4	Val	Gly	Val(25) Gly(>10)	(Val) (Gly)					
5	Glu	Lys	Glu(>10) Lys(>10)	(Glu) (Lys)	(Glu) (Lys)				
6	Glu	Pro	Glu(>10) Pro(>10)	(Glu) (Pro)	(Glu) –				
7	Pro	Gln	Pro(20) Gln(15)	(Pro) (Gln)	- (Gln)				
8	His	Tyr	His(10) Tyr(15)	– (Tyr)	- (Tyr)				
9	Thr	Met	Thr(10) Met(10)	(Thr) (Met)	- (Met)				
10	Glu	Val	(Glu) (Val)						
11	Thr	Leu	(Thr) (Leu)						
12	Val	Val	(Val)						

^a Additional background could be interpreted as being derived from the known N-terminal sequences of the respective proteinase as discussed in the text

Positions not properly identified are shown by dashes. Two preparations of $\alpha_2 M$ —trypsin complex were analysed with similar results, using material from pools 1 and 2 (fig.1). About 10 nmol was used for each degradation. One preparation each of $\alpha_2 M$ —plasmin and $\alpha_2 M$ —thrombin complex, respectively, (pools 1 + 2 material, 12 nmol) were analysed with similar results (not quantitated). Brackets indicate residues identified but not quantitated

b PTH amino acids were analysed and quantitated by HPLC

Table 2	
Major ^a N-terminal sequences of elastase-treated α ₂ N	1

New N-terminal Original N-terminal 1 Gly Ser Gly(>10) Phe(>10) Ser(>10 2 Phe Val Phe(20) Tyr(<10) Val(20) 3 Tyr Ser Tyr(15) Ser(>10 4 Glu Gly Glu(>10) Gly(>10 5 Ser Lys Ser(<10) Lys(20) 6 Asp Pro - - 7 Val Gln Val(10) Gln(10) 8 Met Tyr Met(10) Tyr(15)	Position	Known seque (fig.2,3)	nces	Residues detected (nmol) ^b after proteolytic cleavage of $\alpha_2 M$ with elastase				
2 Phe Val Phe(20) Tyr(<10)			_					
3 Tyr Ser Tyr(15) Ser(>16 4 Glu Gly Glu(>10) Gly(>14 5 Ser Lys Ser(<10) Lys(20) 6 Asp Pro 7 Val Gln Val(10) Gln(10) 8 Met Tyr Met(10) Tyr(15) 9 Gly Met Gly(10) Met(15) 10 Arg Val - (Val)	1	Gly	Ser	Gly(>10) Phe(>10)	Ser(>10)			
4 Glu Gly Glu(>10) Gly(>14) 5 Ser Lys Ser(<10) Lys(20) 6 Asp Pro 7 Val Gln Val(10) Gln(10) 8 Met Tyr Met(10) Tyr(15) 9 Gly Met Gly(10) Met(15) 10 Arg Val - (Val)	2	Phe	Val	Phe(20) $Tyr(<10)$	Val(20)			
5 Ser Lys Ser(<10) Lys(20) 6 Asp Pro - - 7 Val Gln Val(10) Gln(10) 8 Met Tyr Met(10) Tyr(15) 9 Gly Met Gly(10) Met(15) 10 Arg Val - (Val)	3	Tyr	Ser	Tyr(15)	Ser(>10)			
6 Asp Pro — — 7 Val Gln Val(10) Gln(10) 8 Met Tyr Met(10) Tyr(15) 9 Gly Met Gly(10) Met(15) 10 Arg Val — (Val)	4	Glu	Gly	Glu(>10)	Gly(>10)			
7 Val Gln Val(10) Gln(10) 8 Met Tyr Met(10) Tyr(15) 9 Gly Met Gly(10) Met(15) 10 Arg Val - (Val)	5	Ser	Lys	Ser(<10)	Lys(20)			
8 Met Tyr Met(10) Tyr(15) 9 Gly Met Gly(10) Met(15) 10 Arg Val - (Val)	6	Asp	Pro		_			
9 Gly Met Gly(10) Met(15) 10 Arg Val - (Val)	7	Val	Gln	Val(10)	Gln(10)			
10 Arg Val - (Val)	8	Met	Tyr	Met(10)	Tyr(15)			
	9	Gly	Met	Gly(10)	Met(15)			
11 Gly Leu (Gly) (Leu)	10	Arg	Val		(Val)			
	11	Gly	Leu	(Gly)	(Leu)			
12 His Val – (Val)	12	His	Val	-	(Val)			

a Additional background could be interpreted as being derived from the known N-terminal sequence of elastase

Positions not properly identified are shown by dashes; 10 nmol of pools 1 and 2 material from one preparation of α_2 M—elastase complex was degraded with similar results. Brackets indicate residues identified but not quantitated




Fig. 3. Amino acid sequence of a 35 residue stretch from the middle of the α_2 M subunits containing the cleavage sites for trypsin (plasmin, thrombin) and for elastase, respectively. Peptide nomenclature: CB-O and CB-P, CNBr fragments from α_2 M; T2, tryptic peptide from reduced, carboxymethylated, citraconylated α_2 M; CB-PT1-3, tryptic peptides from CB-P; CB-PSP1, peptide from maleylated CB-P obtained after digestion with a protease from Staphylococcus aureus strain V8; CB-PC1-2 chymotryptic peptides from CB-P. Because its N-terminal was blocked the sequence of CB-PSP1 was deduced from the sequences of its three tryptic subpeptides corresponding to CB-PT1-2 and residues 1-10 of CB-PT3: (1) the cleavage site for trypsin (plasmin, thrombin) and the major cleavage site for elastase; ($^{\circ}$ V) minor cleavage site for elastase; T, trypsin; Pl, Plasmin; Th, thrombin; E, elastase.

b PTH amino acids were analysed and quantitated by HPLC

The new N-terminal sequence revealed at the trypsin cleavage site was deduced as:

The new N-terminal sequence deduced for the elastase cleavage site was:

The results (table 2) also indicate the presence of an additional minor new N-terminal $\alpha_2 M$ -sequence in the $\alpha_2 M$ -elastase, namely Phe-Tyr-. By manual sequence determination, however, 4 residues of the latter sequence could be deduced extending it to:

The 3 sequences thus identified form part of a 298 residue stretch in the part of $\alpha_2 M$ already sequenced. Fig.3 shows the relative positions of these cleavage sites in a 35 residue segment of this 298 residue stretch. The sequence of this segment had been deduced by

combining data from amino acid analysis (table 3) and manual sequence determination. The minimal evidence required to prove the sequence is presented in fig.3 (redundant information not included). Despite the fact that plasmin and thrombin cleaved $\alpha_2 M$ only to $\sim 50\%$ the characteristic sequence:

In addition to the major sequences derived from $\alpha_2 M$ itself part of the known N-terminal sequence of the proteinase, namely Ile-1, Gly-3, Tyr-5, Ala-9 of trypsin in a yield of 0.3 mol/mol $\alpha_2 M$ -subunit and Val-1, Gly-3, Ala-7, Asn-10 of elastase in a yield of 0.25 mol/mol $\alpha_2 M$ -subunit, was recognized as 'background'. In $\alpha_2 M$ -thrombin Glu-3 and Ala-7 from the enzyme and in $\alpha_2 M$ -plasmin Val-1, Gly-3, Val-6 and Ala-7 were recognized in lower yield.

Table 3

Amino acid composition, yields and electrophoretic mobilities of peptides used for deducing the sequences of the two stretches from $\alpha_n M$ shown in fig. 2, 3^a

	CB-A	СВ-В	T1	T2	CB-O	CB-PT1	CB-PT2	CB-PT3	CB-PSP1	CB-PC1	CB-PC2
CmCys		1.6 (2)									
Asx		6.0 (6)		1.0(1)	1.0(1)						
Thr		5.6 (6)	2.9(3)					2.0(2)	0.8(1)		
Ser	1.8(2)	7.7 (8)	2.7(3)	0.8(1)	0.8(1)						
Glx	1.0(1)	8.7 (8)	3.2(3)	1.0(1)	2.3(2)			3.1(3)	<u>3.0</u> (3)		
Pro	0.9(1)	2.3 (2)	2.1(2)		1.1(1)			1.1(1)	1.0(1)		
Gly	1.0(1)	2.3 (2)	1.0(1)	1.8(2)	3.0(3)	1.0 (1)	1.0(1)		1.8(2)	<u>2.0(2)</u>	
Ala		4.2 (4)					0.9(1)		0.8(1)		1.0(1)
Val	1.2(1)	11.0(10)	3.3(3)	1.9(2)	2.3(2)			3.1(3)	1.9(2)		
Met ^d	+ (1)	+ (1)	0.9(1)	0.8(1)	+ (1)						
Ile											
GlcN		+									
Leu		10.2(10)	3.1(3)					1.0(1)	1.1(1)		<u>1.0(1)</u>
Tyr	1.1(1)	1.0 (1)	1.0(1)	1.2(1)	0.9(1)						
Phe	, ,	2.2 (2)	, ,	1.2(1)	0.9(1)						
Lys	1.0(1)	2.2 (2)	2.0(2)	` '		$0.8(0)^{e}$					
His		1.9 (2)	1.0(1)		0.9(1)		1.0(1)	2.0(2)	2.6(3)	1.0(1)	
Arg		2.0 (2)	. ,	<u>1,0</u> (1)	0.9(1)	1.0(1)	1.0(1)	1.0(1)	2.1(2)	0.9(1)	1.0(1)
Yield(%)	10	30	12	15	16	10	15	25	14	5	21
m 6.5b	-0.27	-	-0.06	-0.23	0.35	-0.77	-0.68	0	$0^{\mathbf{f}}$	-0.68	-0.73
m 1.9°	0.95		0.95	0.84	0.92			1.32			

The compositions are listed as molar ratios with the residue used as a basis for the calculation underlined. The number of residues expected from the sequence analysis is listed in brackets. The values are not corrected for incomplete hydrolysis losses

b Electrophoretic mobility relative to aspartic acid at pH 6.5; ^c Electrophoretic mobility relative to serine at pH 1.9; ^d Homoserine and homoserine lactone in CNBr fragments were not quantitated; ^e CB-PT1 was contaminated with free lysine; ^f CB-PSP1 was carbamylated

4. Discussion

Assuming an initial coupling yield of 60% the N-terminal sequence of $\alpha_2 M$ was recovered in a yield compatible with $\alpha_2 M$ being composed of 4 identical subunits of M_r 180 000 [14,17].

Moreover, the yield of the additional N-terminal sequence exposed as a result of the specific cleavage by trypsin or elastase during their complex formation with $\alpha_2 M$ was essentially the same as that obtained for the original N-terminal sequence, showing that the sequences of all 4 subunits are identical in this region, and also that complete cleavage of all 4 subunits had occurred at closely spaced sites in the 'bait' region. Trypsin, plasmin and thrombin were found to cleave at the same Arg-Leu bond (fig.3). Whether additional cleavage had occurred at the Arg-Val and Arg-Gly bonds located 4 and 15 residues before the Arg-Leu bond is not known, since the resulting small peptides would have escaped detection in the present experiments. Elastase was found to cleave $\alpha_2 M$ in 2 other places, a major cleavage at the Val-Gly bound and a minor cleavage at the following Gly-Phe bond in the 'bait' region sequence (fig.3). The 2 elastase-cleavage sites are located 13 and 14 residues before the common trypsin-plasmin-thrombin cleavage site, showing that the bait region comprises at least 15 residues.

Although it is not known whether cleavage of any peptide bond within the bait region will lead to formation of $\alpha_2 M$ —proteinase complexes, these data show that cleavage of $\alpha_2 M$ by the proteinases investigated reflects their primary substrate specificity. This indicates that only those proteinases which can cleave (a) specific bond(s) within the bait region can form a complex with $\alpha_2 M$. The trypsin/thrombin/plasmin cleavage site is located $\sim 665-700$ residues from the N-terminal.

The stability of $\alpha_2 M$ —proteinase complexes during SDS—PAGE under reducing conditions suggests that the proteinase binds covalently to $\alpha_2 M$ [30–32]. This conclusion is supported by earlier results [15] and the present finding, that most of the proteinase is not released from $\alpha_2 M$ —proteinase complexes during gel filtration under denaturing conditions (fig.1). Furthermore the N-terminal sequences of the proteinases were recognized in the $\alpha_2 M$ -complexes. The 4 chains of $\alpha_2 M$ [16,33] and the α' -chain part of complement component C3 [34,35] both contain an internal reactive thiol ester, involving the γ -carboxyl group of the Glx-residue and the thiol group of the Cys-residue

[33,34] in the identical heptapeptide sequences: Gly-Cys-Gly-Glu-Glx-Asn-Metin the 2 proteins [33,34,36]. The Glx-residue is located ~256 residues after the tryptic cleavage site in the bait region. Upon activation of $\alpha_2 M$ by trypsin or pancreatic elastase [16] and of C3 with trypsin [34,35] their thiol ester group/s is/are rapidly cleaved resulting in the appearance of SH-groups [16,34,35]. On the basis of these results it has been suggested that $\alpha_2 M$ and C3, when activated, participate in 'acyl-transfer' reactions, leading to the formation of covalent bonds between α₂M and proteinase [16] or between C3 and specific cell-surface structures [34,35]. Because the 'bait' region cleavage reflects the specificity of the proteinase the 'initial' α₂M-proteinase complex must involve the active site of the proteinase binding to the 'bait' region of α_2 M. Because the 'final' complex, which presumably involves the thiol-esterified Glx of α_2 M [16], is active against small substrates for the proteinase it cannot involve the active site of the proteinase. Thus, $\alpha_2 M$ -proteinase complex formation occurs in at least 2 structurally well-defined steps. The 'final' complex is rapidly removed from the circulation [37], being taken up by cells, e.g., macrophages and fibroblasts [38–40]. Therefore, the formation of $\alpha_2 M$ – proteinase complexes following cleavage of a single peptide bond in the 'bait' region can now be recognized as another example of a physiological process activated by specific limited proteolysis. Because baitregion cleavage in α₂M and anaphylatoxin release from C3 and C5 now seem to play corresponding roles in the 'activation' of these proteins the sequence preceding the cleavage sites in the bait region of $\alpha_2 M$ was




Fig.4. Sequence similarities found by comparing the total sequences of anaphylatoxins C3a and C5a with the 80-odd residue sequence of $\alpha_2 M$ preceding the bait region cleavage sites for trypsin/thrombin/plasmin and for elastase. Identities between the complement components on the one hand and one of the $\alpha_2 M$ -sites on the other are underlined. Mutually identical residues between the 2 $\alpha_2 M$ -sites are boxed. $^a \alpha_2 M$, the trypsin, thrombin, plasmin-cleavage site; $^b \alpha_2 M$, the major elastase-cleavage site.

compared with the mutually homologous sequences of C3a and C5a [41] by visual inspection. The sequence similarities found in the last 14–17 residues before the cleavage sites (fig.4) may be the result of analogous/homologous evolution of these parts of $\alpha_2 M$ and the 2 complement components.

Acknowledgements

Excellent technical assistance was given by Laila Brøns, Lone Christensen, Mette Frandsen, Rita Hansen, Claire Jones and Lene Kristensen. T. M. S. was a recipient of a Canadian Medical Research Council post-doctoral fellowship. Outdated human plasma was obtained from The Blood Bank, Aarhus University Hospital through the courtesy of F. Kissmeyer-Nielsen, J. Jørgensen and S. Steenbjerg. This work was supported by The National Heart, Lung and Blood Institute, NIH, Bethesda MD, grant HL16238 and by grants 13X-3532 from The Swedish Medical Research Council and from Knut and Alice Wallenberg's Foundation.

References

- [1] Schönenberger, M. V., Schmidtberger, R. and Schultze, H. E. (1958) Z. Naturforsch. 13B, 761-772.
- [2] Jones, J. M., Creeth, J. M. and Kekwick, R. A. (1972) Biochem. J. 127, 187-197.
- [3] Barrett, A. J. and Starkey, P. M. (1973) Biochem. J. 133, 709-724.
- [4] Werb, Z., Burleigh, M. C., Barrett, A. J. and Starkey, P. M. (1974) Biochem. J. 139, 359-368.
- [5] Starkey, P. M. and Barrett, A. J. (1977) in: Proteinases in Mammalian Cells and Tissues (Barrett, A. J. ed) pp. 663-696, Elsevier/North-Holland, Amsterdam, New York.
- [6] Mehl, J. W., O'Connell, W. and DeGroot, J. (1964) Science 145, 821–822.
- [7] Ganrot, P. O. (1967) Ark. Kemi 26, 583-591.
- [8] Lanchantin, G. F., Plesset, M. D., Friedman, J. A. and Hart, D. W. (1966) Proc. Soc. Exp. Biol. Med. 121, 444-449.
- [9] Niléhn, J.-O. and Ganrot, P. O. (1967) Scand. J. Clin. Lab. Invest. 20, 113–121.
- [10] Barrett, A. J., Starkey, P. M. and Munn, E. A. (1974) in: Proc. Vth Bayer Symp. Proteinase Inhibitors (Fritz, H. et al. eds) pp. 72-77, Springer, Berlin, New York.
- [11] Barrett, A. J., Brown, M. A. and Sayers, C. A. (1979) Biochem. J. 181, 401-418.
- [12] Hall, P. K. and Roberts, R. C. (1978) Biochem. J. 171, 27-38.
- [13] Harpel, P. C. (1973) J. Exp. Med. 138, 508-521.
- [14] Swenson, R. P. and Howard, J. B. (1979) J. Biol. Chem. 254, 4452-4456.

- [15] Pochon, F., Amand, B., Lavalette, D. and Bieth, J. (1978) J. Biol. Chem. 253, 7496-7499.
- [16] Sottrup-Jensen, L., Petersen, T. E. and Magnusson, S. (1980) FEBS Lett. 121, 275-279.
- [17] Sottrup-Jensen, L., Stepanik, T. M., Jones, C. M., Petersen, T. E. and Magnusson, S. (1979) in: The Physiological Inhibitors of Blood Coagulation and Fibrinolysis (Collen, D. et al. eds) pp. 255-271, Elsevier/ North-Holland, Amsterdam, New York.
- [18] Chibber, B. A. K., Deutsch, D. G. and Mertz, E. T. (1974) Methods Enzymol. 34, 424–432.
- [19] Magnusson, S. (1970) Methods Enzymol. 19, 157-188.
- [20] Houmard, J. and Drapeau, G. R. (1972) Proc. Natl. Acad. Sci. USA 69, 3506-3509.
- [21] Sottrup-Jensen, L., Claeys, H., Zajdel, M., Petersen, T. E. and Magnusson, S. (1978) in: Progr. Chem. Fibrinol. Thrombol. (Davidson, J. F. et al. eds) vol. 3, pp. 191-209, Raven, New York.
- [22] Edman, P. and Henschen, A. (1975) in: Protein Sequence Determination (Needleman, S. B. ed) pp. 232-279, Springer, Berlin, New York.
- [23] Tarr, G. E. (1977) Methods Enzymol. 47, 335-357.
- [24] Petersen, J. D., Nehrlich, S., Oyer, P. E. and Steiner, D. F. (1972) J. Biol. Chem. 247, 4866-4871.
- [25] Sottrup-Jensen, L., Petersen, T. E. and Magnusson, S. (1980) Anal. Biochem. 107, 456-460.
- [26] Jörnvall, H. and Philipson, L. (1980) Eur. J. Biochem. 104, 237-247.
- [27] Sottrup-Jensen, L., Zajdel, M., Claeys, H., Petersen, T. E. and Magnusson, S. (1975) Proc. Natl. Acad. Sci. USA 72, 2577-2581.
- [28] Moore, S. (1968) J. Biol. Chem. 243, 6281-6283.
- [29] Dunn, J. T. and Spiro, R. G. (1967) J. Biol. Chem. 242, 5549-5555.
- [30] Steinbuch, M., Audran, R., Lambin, P. and Fine, J. M. (1976) Protides Biol. Fluids 23, 133-138.
- [31] Harpel, P. C. and Rosenberg, R. D. (1976) Prog. Thromb. 3, 145-189.
- [32] Salvesen, G. S. and Barrett, A. J. (1980) Biochem. J. 187, 695-701.
- [33] Sottrup-Jensen, L., Hansen, H. F., Mortensen, S. B., Petersen, T. E. and Magnusson, S. (1981) FEBS Lett. 123, 145-148.
- [34] Tack, B. F., Harrison, R. A., Janatova, J., Thomas, M. L. and Prahl, J. W. (1980) Proc. Natl. Acad. Sci. USA 77, 5764-5768.
- [35] Pangburn, M. K. and Müller-Eberhard, H. J. (1980) J. Exp. Med. 152, 1102-1114.
- [36] Swenson, R. P. and Howard, J. B. (1979) Proc. Natl. Acad. Sci. USA 76, 4313-4316.
- [37] Ohlsson, K. (1976) Protides Biol. Fluids 23, 43-45.
- [38] Debanne, M. T., Bell, R. and Dolovich, J. (1975) Biochim. Biophys. Acta 411, 295-304.
- [39] Van Leuven, F., Cassiman, J.-J. and Van den Berghe, H. (1979) J. Biol. Chem. 254, 5155-5160.
- [40] Kaplan, J. and Nielsen, M. L. (1979) J. Biol. Chem. 254, 7329-7335.
- [41] Porter, P. R. and Reid, K. B. M. (1979) Adv. Protein Chem. 33, 1-71.